5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-(β-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry
| Autor: | Maria Rosaria Cesarone, I. Ruffini, Marcello Corsi, Gianni Belcaro, Andrea Di Renzo, Andrea Ledda, Edmondo Ippolito, M G Grossi, Mark Dugall, Marisa Cacchio, Anna Rita Marino Santarelli, Andrea Ricci |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
medicine.medical_specialty Time Factors Chronic venous insufficiency Administration Oral Capillary filtration Severity of Illness Index Drug Administration Schedule Group B law.invention Capillary Permeability Randomized controlled trial law Edema Diabetes mellitus Varicose veins Laser-Doppler Flowmetry Humans Medicine Prospective Studies Registries Skin Dose-Response Relationship Drug business.industry Microangiopathy Cardiovascular Agents Middle Aged medicine.disease Surgery Hydroxyethylrutoside Treatment Outcome Venous Insufficiency Anesthesia Chronic Disease Patient Compliance medicine.symptom Cardiology and Cardiovascular Medicine business Blood Gas Monitoring Transcutaneous Venous Pressure Blood Flow Velocity Diabetic Angiopathies Stockings Compression |
| Zdroj: | Angiology. 59:14S-20S |
| ISSN: | 1940-1574 0003-3197 |
| DOI: | 10.1177/0003319707312683 |
| Popis: | This independent prospective controlled trial evaluates the efficacy of O-(β-hydroxyethyl)-rutosides (HR) during 5 years of administration against signs and symptoms and further degeneration of microcirculatory disturbances. The protective effect of HR in preventing end-point complications such as venous ulceration is evaluated. This study is based on evaluation of edema and the capillary filtration rate (CFR) in association with a clinical score scale. Patients having a severe degree of chronic venous insufficiency (CVI) and venous microangiopathy and completing at least 5 years of treatment are included. The following 4 groups are considered: group A (patients with CVI but without diabetes mellitus, receiving 1500 mg/d of HR), group B (patients with CVI and diabetes mellitus, receiving 2 g/d of HR), group C (control subjects receiving no pharmacologic or compression treatment), and group D (patients using elastic compression stockings only). All patients received the “best” available treatment. No adverse effects or intolerance is noted, with good compliance (>85%). In group A, there is a statistically significant decrease in the CFR during 5 years of follow-up. In group B, the decrease in the CFR is greater than that in group A. Reductions in edema, swelling, and the CFR during 5 years are notable, and values approach normal levels. During 5 years, HR is effective in treating venous edema and hypertension and in preventing deterioration of the distal venous system. The prevention of ulcerations with HR is another important observation. The effects of HR seem to be partially dose related, and tolerability and compliance are good. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|